Vepdegestrant, a proteolysis-targeting chimera (PROTAC) estrogen receptor (ER) degrader, plus atirmociclib (ATI) in ER+/HER2− advanced breast cancer (ABC): TACTIVE-K phase 1b/2 results.

Veppanu (vepdegestrant) - Rigel Pharmaceuticals

atirmociclib (PF-07220060) - Pfizer

https://www.asco.org/abstracts-presentations/261217

Melinda Telli; Lana Tran; Shaparak Lonning; Noah Berkowitz; Yuanyuan Zhang; Marco Mazzoletti; Toru Mukohara; Manuel Ruiz-Borrego; Kan Yonemori; Yanxia Zhao; Komal Jhaveri; Shusen Wang; Amita Patnaik; Jean-Sebastien Frenel; Ping Xu

Apr 21, 2026